Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects of acalabrutinib and duvelisib and how well
they work in treating patients with indolent non-Hodgkin lymphoma that has come back
(relapsed) or does not respond to treatment (refractory). Acalabrutinib inhibits a signaling
molecule called Bruton tyrosine kinase and blocks cancer cell proliferation, growth, and
survival. Duvelisib is designed to block a protein called PI3 kinase in order to stop cancer
growth and cause changes in the immune system that may allow the immune system to better act
against cancer cells. Giving acalabrutinib and duvelisib together may work better to block
cancer growth than therapy of either drug alone.